N-Acetyl Selank Amidate
N-Acetyl Selank Amidate (NASA) is the absolute apex of chemically modified Russian anxiolytic peptides. By capping both ends of the original Selank molecule, researchers created a structurally immortalized variant that violently resists enzymatic breakdown. This hyper-stabilized structure produces an exponentially longer half-life, drastically deeper blood-brain barrier penetration, and an intense, unwavering anxiolytic and profound cognitive-enhancing effect unmatched by the base peptide.
Quick Stats
Scientific Data
Mechanism of Action
N-Acetyl Selank Amidate is the modified, stable form of Selank (a synthetic analog of the endogenous tuftsin peptide TKPR). The N-acetyl and C-terminal amide modifications substantially increase enzymatic stability and intranasal bioavailability vs. standard Selank.
Selank acts primarily as an anxiolytic and nootropic via GABA-A receptor modulation (with no physical dependence), BDNF/NGFF upregulation for neuroprotection, and normalization of serotonin/dopamine/norepinephrine levels. Developed at the Institute of Molecular Genetics (Moscow), it has Phase II clinical data for generalized anxiety disorder. N-Acetyl Selank Amidate is preferred for intranasal use due to superior CNS penetration and stability.
Source: Based on PMID: 18577766
Background & History
N-Acetyl Selank Amidate (NASA) is a chemically stabilized version of Selank — the anxiolytic heptapeptide approved in Russia since 2009. Two chemical modifications solve Selank's major pharmacokinetic weakness: its ~3 minute half-life. N-terminal acetylation blocks aminopeptidase degradation, C-terminal amidation blocks carboxypeptidase attack, extending half-life to 60-90 minutes. This makes intranasal dosing practical — one dose provides sustained CNS effects for hours instead of minutes.
Research Use Cases
- ✓Anxiolysis without benzodiazepine-class side effects (sedation, dependence, amnesia)
- ✓Cognitive enhancement via BDNF and NGF upregulation
- ✓Stress resilience and emotional regulation
- ✓Complement to psychotherapy for generalized anxiety
Dosing Protocol
| Typical Dose | 250-750 mcg/day (intranasal) |
| Frequency | 1-2× daily |
| Half-Life | ~60-90 minutes |
| Common Vial Sizes | 5 mg, 10 mg |
Dosing Protocols
Intranasal Protocol
SubQ Injection
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 250–750 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 193 mcg | 386 mcg | 579 mcg |
| 140 lb(63 kg) | 225 mcg | 450 mcg | 675 mcg |
| 160 lb(73 kg) | 261 mcg | 521 mcg | 782 mcg |
| 180 lb(82 kg) | 293 mcg | 586 mcg | 879 mcg |
| 200 lb(91 kg) | 325 mcg | 650 mcg | 975 mcg |
| 220 lb(100 kg) | 357 mcg | 714 mcg | 1071 mcg |
| 250 lb(113 kg) | 404 mcg | 807 mcg | 1211 mcg |
💉 For exact syringe units based on your vial concentration, use the N-Acetyl Selank Amidate Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
Anxiety / Stress
LowPhase II clinical data for GAD. Non-sedating, non-addictive anxiolytic. Preferred by those seeking benzodiazepine alternatives.
Cognitive Enhancement
LowNootropic effects via BDNF upregulation and neurotransmitter normalization. Improved working memory and focus.
Reconstitution Example
Safety & Considerations
Phase II clinical data in Russia. Well-tolerated in available studies. No physical dependence or withdrawal. May cause mild nasal irritation (intranasal). Start with lower doses.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
May potentiate existing anxiolytic medications (benzodiazepines, SSRIs). Avoid combining with MAO inhibitors — risk of serotonergic interactions. Intranasal delivery bypasses first-pass metabolism — onset faster than subcutaneous. No tolerance, dependence, or withdrawal documented.
Synergies & Common Stacks
Selank (anxiolytic + GABA-focused) pairs naturally with Semax (nootropic + dopaminergic). Together they provide comprehensive cognitive-emotional optimization — a classic Russian peptide stack.
Pinealon supports sleep architecture while NASA provides daytime anxiolysis — complementary chronobiological support without pharmacological overlap.
Dosing Quick Reference
Frequently Asked Questions
What is the difference between Selank and N-Acetyl Selank Amidate?▼
References
- Semenova TP et al. “"Selank in generalized anxiety disorder".” Bulletin of Experimental Biology and Medicine (2010). PMID: 21128050
Get N-Acetyl Selank Amidate from our recommended source — independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.
Affiliate link · Full review